1) NCCN Guide line ; http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf
2) 大腸癌研究会編 : 大腸癌治療ガイドライン 2014年版医師用, 金原出版
3) 大腸癌研究会編 : 大腸癌取扱い規約 第8版, 金原出版
4) Tournigand C, Andre T, Achille E, et al : FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer : a randomized GERCOR study. J Clin Oncol. 2004 Jan 15 ; 22 (2) : 229-37. Epub 2003 Dec 2.
5) Grothey A and Sargent D : Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or singleagent therapy is used first line. J Clin Oncol. 2005 Dec 20 ; 23 (36) : 9441-2.
6) Schmoll HJ, Van Cutsem E, Stein A, et al : ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol. 2012 Oct ; 23 (10) : 2479-516.
7) Saltz LB, Clarke S, Diaz-Rubio E,et al : Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer : a randomized phase III study. J Clin Oncol. 2008 Apr 20 ; 26 (12) : 2013-9.
8) Van Cutsem E, Kohne CH, Hitre E, et al : Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009 Apr 2 ; 360 (14) : 1408-17.
9) Douillard JY, Siena S, Cassidy J, et al : Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer : the PRIME study. J Clin Oncol. 2010 Nov 1 ; 28 (31) : 4697-705.
10) Giantonio BJ, Catalano PJ, Meropol NJ, et al : Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer : results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007 Apr 20 ; 25 (12) : 1539-44.
11) Bennouna J, Sastre J, Arnold D, et al : Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147) : a randomised phase 3 trial. Lancet Oncol. 2013 Jan ; 14 (1) : 29-37.
12) Sobrero AF, Maurel J, Fehrenbacher L, et al : EPIC : phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol. 2008 May 10 ; 26 (14) : 2311-9.
13) Alberto F. Sobrero, Marc P, Timothy JP, et al : Final results from study 181 : Randomized phase III study of FOLFIRI with or without panitumumab (pmab) for the treatment of second-line metastatic colorectal cancer (mCRC). J Clin Oncol. 2012 Gastrointestinal Cancers Symposium. Vol 30, No 4_suppl (February 1 Supplement), 2012 : 387
14) Yamada Y, Takahari D, Matsumoto H, et al : Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT) : an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol. 2013 Dec ; 14 (13) : 1278-86.
15) Maughan TS, Adams RA, Smith CG, et al : Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer : results of the randomised phase 3 MRC COIN trial. Lancet. 2011 Jun 18 ; 377 (9783) : 2103-14.
16) Volker H, Ludwig F, Thomas D, et al : Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer : German AIO study KRK-0306 (FIRE-3). J Clin Oncol. 2013 ASCO Annual Meeting Abstracts.Vol 31, No 15_suppl (May 20 Supplement), 2013
17) Jonker DJ, O'Callaghan CJ, Karapetis CS, et al : Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007 Nov 15 ; 357 (20) : 2040-8.
18) Van Cutsem E, Peeters M, Siena S, et al : Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007 May 1 ; 25 (13) : 1658-64.
19) J. Douillard, S. Siena, J. Cassidy,et al : Final results from PRIME : Randomized phase III study of panitumumab (pmab) with FOLFOX4 for first line metastatic colorectal cancer (mCRC). J Clin Oncol, 2011 ASCO Annual Meeting Abstracts. Vol 29, No 15_suppl (May 20 Supplement), 2011 : 3510
20) Kelly S. Oliner, Douillard JY, Salvatore S, et al : Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC). J Clin Oncol. 2013 ASCO Annual Meeting Abstracts.Vol 31, No 15_suppl (May 20 Supplement), 2013 : 3511
21) de Gramont A, Figer A, Seymour M, et al : Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000 Aug ; 18 (16) : 2938-47.
22) Hurwitz H, Fehrenbacher L, Novotny W, et al. : Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004 Jun 3 ; 350 (23) : 2335-42.
23) Cunningham D, Lang I, Marcuello E, et al : Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX) : an open-label, randomised phase 3 trial. Lancet Oncol. 2013 Oct ; 14 (11) : 1077-85.
24) Falcone A, Ricci S, Masi G et al ; Gruppo Oncologico Nord Ovest. ;Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer : the Gruppo Oncologico Nord Ovest. ; J Clin Oncol. 2007 May 1 ; 25 (13) : 1670-6.
25) Fotios L, Chiara C, Gianluca M, et al : FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCRC) : Results of the phase III randomized TRIBE trial. J Clin Oncol, 2013 Gastrointestinal Cancers Symposium (January 24-26, 2013). Vol 31, No 4_suppl (February 1 Supplement), 2013 : 336
26) Alfredo F, Chiara C, Gianluca M, et al : FOLFOXIRI/Bevacizumab (Bev) versus FOLFIRI/Bev as 1st-line Treatment in Unresectable Metastatic Colorectal Cancer (mCRC) Patients (pts) : Results of the Phase III TRIBE Trial by GONO group. ; J Clin Oncol, 2013 ASCO Annual Meeting Abstracts. Vol 31, No 15_suppl (May 20 Supplement), 2013 : 3505
27) Wong R, Cunningham D, Barbachano Y, et al : A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol. 2011 Sep ; 22 (9) : 2042-8.
28) Leone F, Artale S, Marino D, et al : Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases. The MetaPan study. Cancer. 2013 Oct 1 ; 119 (19) : 3429-35.
29) Folprecht G, Gruenberger T, Bechstein WO, et al : Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab : the CELIM randomised phase 2 trial. Lancet Oncol. 2010 Jan ; 11 (1) : 38-47.
30) Folprecht G et al ESMO 2013
31) Gunnar F, Thomas G, Wolf B, et al : Cetuximab and chemotherapy in the treatment of patients with initially "nonresectable" colorectal (CRC) liver metastases : Long-term follow-up of the CELIM trial. J Clin Oncol, 2013 ASCO Annual Meeting Abstracts.Vol 31, No 15_suppl (May 20 Supplement), 2013 : 3538
32) Doi T, Boku N, Kato K, et al : Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol. 2010 Oct ; 40 (10) : 913-20.
33) Grothey A. Oxaliplatin-safety profile : neurotoxicity. Semin Oncol. 2003 Aug ; 30 (4 Suppl 15) : 5-13.
34) Miyajima R, Kawazoe H, Tsuneoka K, et al : Preventive trial of preheating administration of oxaliplatin-diluted solution in combination with a hot compress for oxaliplatin-induced venous pain. Gan To Kagaku Ryoho. 2013 Apr ; 40 (4) : 537-40.
35) Haller DG. et al : Safety of oxaliplatin in the treatment of colorectal cancer. Oncology (Williston Park). 2000 Dec ; 14 (12 Suppl 11) : 15-20.
36) Matsuyama K, Mishima H, Ueno H, et al : Etiology and management of venous pain during intravenous administration of oxaliplatin. Gan To Kagaku Ryoho. 2011 Mar ; 38 (3) : 411-4.
37) Ando Y, Saka H, Ando M, et al : Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity : a pharmacogenetic analysis. Cancer Res. 2000 Dec 15 ; 60 (24) : 6921-6.
38) 坂田優 : Progress in Medicine, 199818 (4), 774,
39) Dany Abigerges et al : Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl. Cancer Inst., 1994 86 (6), 446,
40) 田口哲也, 西村元一 : Hand-Foot Syndrome Atlas (第三版)
41) Jo Skai, Yasushi Inoue,Hiroya Kashiwagi, et al : Multi-institutional survey on lacrimal side effect of TS-1. Jpn J Clin Ophthalmol. 2012 66 (3) : 271-274.